EZH2 and colorectal cancer: In their cited work [147], the authors showed that the reduced levels of H3K27me3 achieved by EPZ-6438 EZH2 inhibitor promoted HCT116 and SW620 colorectal cancer cells’ resistance to oxaliplatin.